No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While its primary operations are in Japan, the company maintains an international presence through import and export activities, extending its reach to countries including the United States, Belgium, Finland, the Netherlands, Taiwan, and Thailand. Its extensive product lineup includes a wide array of immunoassay test kits designed for detecting pathogens such as influenza viruses, RS virus, human metapneumovirus, Streptococcus pneumoniae, Legionella, Mycoplasma pneumoniae, adenovirus, rotavirus, norovirus, and Group A streptococcus. Additionally, Mizuho Medy offers kits for pregnancy, ovulation, and fecal occult blood screening. The company also provides advanced tools like gene analysis instruments and specialized diagnostic kits for SARS-CoV-2 detection and Mycoplasma pneumoniae nucleic acid analysis.

• HLB Pharmaceutical Co., Ltd
• Koa Shoji Holdings Co.,Ltd.
• Orient Pharma Co., Ltd.
• Essex Bio-Technology Limited
• Dawnrays Pharmaceutical (Holdings) Limited
• SIGA Technologies, Inc.
• JW Holdings Corporation
• Windlas Biotech Limited